BPDCN in Young Patients: What Is the Next Step When Induction Does Not Achieve Complete Remission?

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy. For young, fit patients who are candidates for allogeneic stem cell transplantation, treatment follows a defined sequence with strict response benchmarks at each stage.

Clinical profile: Young age — fit — candidate for allogeneic stem cell transplantation. In this population, initial therapy is aimed at achieving the deepest possible response in preparation for the next step.

Previous treatment line & its unmet goals

Induction therapy — which may include tagraxofusp (SL-401), HCVAD, 7+3, or CHOP — is given in the first treatment line. The goals of induction are strict: normalization of peripheral blood counts; bone marrow blasts below 5%; regression of nodal, splenic, and hepatic masses; and complete clearance of all skin lesions with no new lesions. When these complete remission criteria are not fully met, this protocol defines what happens next.

What this protocol involves

This protocol involves a transplant-based approach — recognized as the only known potentially curative treatment for BPDCN in eligible patients. The full eligibility criteria, timing, and procedural detail are available in the structured protocol below.

Instant Access to Structured Evidence-Based Regimens

References

Allogeneic stem cell transplantation (alloSCT) is the only known potentially curative treatment for BPDCN.

For the few young and fit patients who are considered alloSCT candidates, the aim is to achieve complete remission (CR) prior to alloSCT.

DOI: 10.6004/jnccn.2023.7026

View source ↗